Comprehensive Guide to RTK, NRTK, Secondary Messengers, and Signal Desensitization

Secondary Messengers in Intracellular Signaling

• Primary Messengers: These are the extracellular signals or ligands. They are unable to enter the cell directly because of their chemical properties. Instead, they are received by specific receptors located at the plasma membrane.
• Secondary Messengers: These are intracellular signaling molecules generated within the cell in response to the activation of a receptor by a primary messenger. Their primary functions include amplifying the strength of the signal and activating various intracellular signaling pathways.
• Classification of Secondary Messengers:
  • Hydrophilic Messengers: These are water-soluble molecules that act within the aqueous environment of the cytosol. Examples include:
    • Cyclic AMP (cAMP)
    • Cyclic GMP (cGMP)
    • Calcium ($Ca^{2+}$)
    • Inositol $1,4,5$-Triphosphate ($IP_3$)
  • Hydrophobic Messengers: These are lipid-soluble molecules that typically act at the plasma membrane or within lipid bilayers. Examples include:
    • Phosphatidylinositol $3,4,5$-trisphosphate ($PIP_3$)
    • Diacylglycerol (DAG)
  • Gaseous Signals: These are gases that can diffuse through membranes to act as signals. Examples include:
    • Nitric Oxide (NO)
    • Carbon Monoxide (CO)
    • These gases are often associated with physiological responses like vasodilation.

Functional Roles of Specific Secondary Messengers

• Cyclic AMP (cAMP):
  • The primary role of cAMP is the activation of Protein Kinase A (PKA).
  • Once activated, PKA phosphorylates specific target proteins to regulate various cellular functions.
• Phosphatidylinositol $3,4,5$-trisphosphate ($PIP_3$):
  • $PIP_3$ is responsible for the activation of AKT/PKB kinases.
  • These kinases are critical regulators of cell survival, growth, and metabolism.
• Calcium ($Ca^{2+}$) and Inositol $1,4,5$-Triphosphate ($IP_3$):
  • $IP_3$ binds to and opens calcium channels on the Endoplasmic Reticulum (ER).
  • The resulting release of calcium into the cytosol activates Protein Kinase C (PKC).
  • This pathway is involved in processes such as secretion, muscle contraction, and the regulation of gene expression.
• Cyclic GMP (cGMP):
  • cGMP activates Protein Kinase G (PKG).
  • This activation regulates smooth muscle relaxation, platelet function, and vasodilation.
  • In synaptic signaling, cGMP also plays a role in activating $Na^+$ channels.

Mechanisms of Signal Desensitization

• Definition: Desensitization is a regulatory process that occurs when a signal is present at a high concentration for a prolonged period. This mechanism prevents uncontrolled cellular responses, which is vital because unregulated signaling can lead to diseases such as cancer.
• The Desensitization Process:
  1. A prolonged signal leads to a continuously active receptor.
  2. This triggers the activation of GPCR Receptor Kinase (GRK), also known as Beta-Adrenergic Receptor Kinase (BARK).
  3. GRK phosphorylates the receptor, leading to its inactivation.
  4. A protein called beta-arrestin binds to the phosphorylated receptor.
  5. This binding facilitates clathrin/AP2-mediated endocytosis, whereby the receptor is internalized into endosomes.
  6. Within the endosome, the phosphate group is removed by Protein Phosphatase ($PP2A$).
  7. Once dephosphorylated, the receptor is recycled back to the plasma membrane.
• Types of Desensitization:
  • Homologous Desensitization: Only the specific receptor that was activated by the signal becomes desensitized. For example, an epinephrine signal desensitizing only the epinephrine receptor.
  • Heterologous Desensitization: The activation of one receptor leads to the desensitization of a different, non-activated receptor. For example, an epinephrine signal can cause the desensitization of both the epinephrine receptor and the glucagon receptor via PKA-mediated phosphorylation.

Structure and Features of Receptor Tyrosine Kinases (RTK)

• Overview: RTKs are plasma membrane receptors also categorized as enzyme-linked receptors because they possess intrinsic enzymatic activity.
• Intrinsic Activity: They have tyrosine kinase activity within their cytoplasmic domain.
• Evolutionary Context: These are considered recently evolved receptors compared to G-protein coupled receptors.
• State of Existence:
  • Some RTKs exist as monomers in their inactive state, such as the Epidermal Growth Factor (EGF) receptor.
  • Others exist as permanent dimers, such as the insulin receptor, Nerve Growth Factor (NGF) receptor, and Platelet-Derived Growth Factor (PDGF) receptor.
• Structural Domains:
  • Extracellular Ligand-Binding Domain: Located outside the cell to receive signals.
  • Transmembrane Domain: Spans the lipid bilayer.
  • Cytoplasmic Tyrosine Kinase Domain: Contains the catalytic region that enhances enzymatic activity upon phosphorylation.
  • Non-Catalytic Domain: Serves as a docking site for downstream signaling proteins through specialized domains such as Src Homology $2$ (SH2) or Phosphotyrosine Binding (PTB) domains.

RTK Activation and Downstream Signaling

• Activation Mechanism:
  1. A growth factor binds to the receptor.
  2. Binding induces receptor dimerization.
  3. The dimerized subunits perform auto-cross phosphorylation on specific tyrosine residues.
  4. Phosphorylation occurs on the catalytic domain (to increase enzymatic activity) and the non-catalytic domain (to create docking sites).
  5. Downstream signaling proteins recognize and bind to these phosphorylated sites using SH2 or PTB domains. The specific protein that binds determines the activation of a particular pathway.
• Key RTK Ligands and Their Effects:
  • EGF (Epidermal Growth Factor): Binds EGF receptor; regulates cell survival, growth, proliferation, and differentiation.
  • Insulin: Binds Insulin receptor; regulates carbohydrate utilization and protein synthesis.
  • IGF (Insulin-like Growth Factor): Binds IGF receptor; regulates cell growth.
  • NGF (Nerve Growth Factor): Binds TRK receptor; regulates neuron growth.
  • PDGF (Platelet-Derived Growth Factor): Binds PDGF receptor; regulates survival, growth, proliferation, and migration.
  • FGF (Fibroblast Growth Factor): Binds FGF receptor; regulates fibroblast proliferation and limb development.
  • VEGF (Vascular Endothelial Growth Factor): Binds VEGF receptor; regulates angiogenesis.
  • M-CSF (Macrophage Colony Stimulating Factor): Stimulates monocytes and macrophages.

The RAS-MAP Kinase Signaling Pathway

• Pathway Steps:
  1. Growth factor binds to the RTK, leading to activation, dimerization, and auto-cross phosphorylation.
  2. The adapter protein GRB2 (Grap2) binds to the phosphorylated receptor via its SH2 domain.
  3. GRB2 recruits SOS, which is a Guanine nucleotide Exchange Factor (GEF).
  4. SOS facilitates the dissociation of GDP from RAS and the loading of GTP. This converts RAS into its active, GTP-bound state.
  5. Active RAS binds to RAF (a MAP kinase kinase kinase / MAPKKK). RAF is a serine-threonine kinase.
  6. RAF activates MEK, which in turn activates ERK.
  7. ERK translocates into the nucleus and phosphorylates transcription factors, such as ELK.
  8. This leads to the expression of target genes responsible for cell proliferation and the $G_1 \rightarrow S$ phase transition in the cell cycle.
• Scaffold Protein (KSR): Kinase Suppressor of RAS (KSR) is a scaffold protein that physically holds RAF, MEK, and ERK together. This ensures fast signal transduction, prevents crosstalk with other pathways, and eliminates signal amplification.

PI3 Kinase / AKT and mTOR Pathways

• PI3 Kinase / AKT Pathway Mechanism:
  1. Growth factor activates the RTK.
  2. PI3 Kinase (Phosphoinositide $3$-kinase) binds to the non-catalytic domain of the receptor via an SH2 domain.
  3. PI3 Kinase converts $PIP_2$ into the second messenger $PIP_3$.
  4. $PIP_3$ recruits PDK1 and mTORC2 via their Pleckstrin Homology (PH) domains.
  5. PDK1 and mTORC2 work together to activate AKT kinase (a serine-threonine kinase, also known as PKB).
  6. Active AKT inhibits pro-apoptotic proteins such as BAD, FOXO, and GSK3, thereby inhibiting apoptosis and promoting cell survival.
  7. AKT also activates mTOR, leading to cell growth, mRNA translation, and protein synthesis, while inhibiting autophagy.
• Clinical Relevance: A gain-of-function mutation in AKT kinase is often associated with cancer due to the continuous inhibition of apoptosis.
• The mTOR Pathway Regulation:
  • Stress Conditions: Low ATP levels result in high AMP. This activates AMP-dependent kinase, which activates TSC2. The TSC1/2 complex inhibits RHEB, leading to inactive mTOR and a cessation of cell growth.
  • Growth Conditions: Growth factors activate the PI3K/AKT signaling, which keeps RHEB active. Active RHEB activates mTOR, promoting growth and protein synthesis.
  • Rapamycin: This substance inhibits mTORC1 and is utilized as an anti-cancer agent.

PLC-Gamma and NRTK Signaling

• PLC-Gamma Pathway (RTK):
  • Growth factor activates RTK.
  • PLC-gamma binds to the phosphorylated receptor via its SH2 domain.
  • PLC-gamma cleaves $PIP_2$ into two fragments: $IP_3$ and DAG.
  • $IP_3$ triggers calcium release from the ER, and both calcium and DAG activate Protein Kinase C (PKC).
  • Note on Differences: In GPCR signaling, PLC-beta is activated by the $G_{\alpha Q}$ subunit, whereas in RTK signaling, PLC-gamma is activated directly by the receptor.
• Non-Receptor Tyrosine Kinase (NRTK):
  • These receptors lack intrinsic enzymatic activity in their cytoplasmic domain.
  • Instead, tyrosine kinases such as JAK or c-Src are non-covalently associated with the receptor's cytoplasmic domain.
  • Signals for NRTK: Cytokines, interferons, interleukins, growth hormone, and erythropoietin.
  • Activation: Binding of a cytokine causes receptor dimerization. The associated kinases (JAK/Src) cross-phosphorylate both the enzymes and the receptor, initiating downstream signaling.
  • Pathways Activated by NRTK: JAK-STAT, RAS-MAP, PI3K/AKT, and IP3-DAG pathways.

The JAK-STAT Signaling Pathway

• Mechanism:
  1. A cytokine binds to its receptor, causing dimerization.
  2. JAK kinases perform auto-cross phosphorylation.
  3. JAK phosphorylates the cytoplasmic domain of the receptor.
  4. The phosphorylated receptor recruits STAT proteins.
  5. STAT proteins become phosphorylated, dissociate from the receptor, and dimerize.
  6. The STAT dimer translocates to the nucleus and binds to cytokine response elements.
  7. This results in the expression of target genes for immune cell activation and the regulation of immune responses.

Comparative Analysis: RTK, NRTK, and GPCR

Summary of Developmental and Pathological Contexts

• Evolution: RTKs and NRTKs are more recent evolutionary developments compared to the ancient GPCR systems.
• Cancer: Gain-of-function mutations in RTKs, RAS, or AKT lead to constitutive activation of survival and proliferation pathways, resulting in uncontrolled cell growth and cancer.
• Therapeutics: Rapamycin acts as an anti-cancer agent by specifically targeting and inhibiting the mTORC1 complex to halt growth signaling.